HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BPI-3016

has antidiabetic activity

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Fragments: 373
    - BPI-3016: 1
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Gastrointestinal Hormones: 573
    - Proglucagon: 128
      - Glucagon-Like Peptides: 424
        Glucagon-Like Peptide 1: 6089
        BPI-3016: 1

Experts

1.	Chen, Haibo: 1 article (08/2017)
2.	Ding, Lieming: 1 article (08/2017)
3.	He, Erlong: 1 article (08/2017)
4.	Long, Wei: 1 article (08/2017)
5.	Lu, Sisi: 1 article (08/2017)
6.	Ma, Cunbo: 1 article (08/2017)
7.	Tan, Fenlai: 1 article (08/2017)
8.	Wang, Yanping: 1 article (08/2017)
9.	Yan, Dan: 1 article (08/2017)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 08/01/2017 - "BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus." 08/01/2017 - "In conclusion, BPI-3016 retains the effects of GLP-1 with significantly prolonged half-life, making it a promising therapy for type 2 diabetes with once-weekly treatment in the clinic."
2.	Body Weight (Weight, Body) 08/01/2017 - "In vivo activity of BPI-3016 such as its effects on glycemic control, β-cell mass and body weight was evaluated in ob/ob mice, db/db mice, and spontaneous diabetic cynomolgus monkeys. "

Related Drugs and Biologics

1.	Glucagon-Like Peptide 1 (GLP 1)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control